PubMed · 12685443
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
2003. Bibliography.. https://pubmed.ncbi.nlm.nih.gov/12685443/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
A wealth of evidence has surfaced in the last three years to challenge age-old notions of stem cell compartments in mammalian adult tissues. It was only recently realised that large cellular infusions in clinical practice might contain stem cells with flexible fate potential. This review discusses the current status of the occurence of epithelial chimerism after hematopoietic cell transplantation and presents existing data on detection methodology, characteristics, underlying mechanisms, physiological implications and clinical significance.
The article discusses views and recommendations of the World Marrow Donor Association concerning ethical issues related to the donation of hematopoietic stem cell products with respect to recruitment, evaluation, workup, and follow-up of unrelated donors. Particular emphasis is placed upon commitment of individual donors, in particular, with respect to the needs of patients to find HLA-matched donors, who may be asked to donate stem cell and other cell products more than once for given patients.
Multiple myeloma (MM) is an incurable hematological malignancy with an average survival of 3 years with conventional therapy. Allogeneic hematopoietic cell transplantation (allo-HCT) may cure some patients, but has been associated with a very high transplantation-related mortality (TRM) of over 40%.(1) In contrast to allo-HCT, autologous hematopoietic cell transplantation (AHCT) has been much safer, with a TRM <3% in the 1990s. Therefore, in the last 15 years AHCT has become a common procedure for MM patients. The widespread use of AHCT has been associated with a median survival of 55-72 months,(2,3,4,5,6) and two large randomized trials have shown that AHCT is superior to conventional chemotherapy for the treatment of MM.(3,7) Approaches to improve the outcome of stem cell transplantation for MM patients include consideration of patient status, efficacy and toxicity of induction therapy, source of hematopoietic rescue, conditioning regimens, and maintenance therapy. Recent attempts to improve outcome include tandem AHCT, AHCT followed by RIC (reduced intensity conditioning) allo-HCT, and allo-HCT with T-cell depletion and subsequent donor-lymphocyte infusions (DLI), while novel therapies and improved supportive care may improve the overall survival (OS) of all MM patients with or without transplantation.